An emerging role for endothelial barrier support therapy for congenital disorders of glycosylation
- PMID: 32064623
- DOI: 10.1002/jimd.12225
An emerging role for endothelial barrier support therapy for congenital disorders of glycosylation
Abstract
Congenital disorders of glycosylation (CDGs) are clinically heterogeneous disorders defined by a decreased ability to modify biomolecules with oligosaccharides. Critical disruptions in protein recognition, interaction, binding, and anchoring lead to broad physiological effects. Patients present with endocrinopathy, immunodeficiency, hepatopathy, coagulopathy, and neurodevelopmental impairment. Patients may experience mortality/morbidity associated with shock physiology that is frequently culture negative and poorly responsive to standard care. Oedema, pleural and pericardial effusions, ascites, proteinuria, and protein-losing enteropathy are observed with an exaggerated inflammatory response. The negative serum protein steady state results from several mechanisms including reduced hepatic synthesis and secretion, increased consumption, and extravasation. Disruption of the glycocalyx, a layer of glycosylated proteins that lines the endothelium preventing thrombosis and extravasation, is a suspected cause of endothelial dysfunction in CDG patients. We performed a retrospective review of CDG patients admitted to our institution with acute illness over the past 2 years. Longitudinal clinical and laboratory data collected during the sick and well states were assessed for biomarkers of inflammation and efficacy of interventions. Six patients representing 4 CDG subtypes and 14 hospitalisations were identified. Acute D-dimer elevation, proteinuria, decreased serum total protein levels, coagulation proteins, and albumin were observed with acute illness. Infusion of fresh frozen plasma, and in some cases protein C concentrate, was associated with clinical and biomarker improvement. This was notable with intra-patient comparison of treated vs untreated courses. Use of endothelial barrier support therapy may reduce endothelial permeability by restoring both regulatory serum protein homeostasis and supporting the glycocalyx and is likely a critical component of care for this population.
Keywords: congenital disorders of glycosylation; endothelial barrier support therapy; extravasation; fresh frozen plasma; glycocalyx; septic shock.
© 2020 SSIEM.
Similar articles
-
Endothelial Glycocalyx Impairment in Disease: Focus on Hyaluronan Shedding.Am J Pathol. 2020 Apr;190(4):768-780. doi: 10.1016/j.ajpath.2019.11.016. Epub 2020 Feb 6. Am J Pathol. 2020. PMID: 32035885 Review.
-
[Glycocalyx is an active part of the endothelium].Lakartidningen. 2016 May 13;113:DXUS. Lakartidningen. 2016. PMID: 27187696 Review. Swedish.
-
Targeting Endothelial Dysfunction in Acute Critical Illness to Reduce Organ Failure.Anesth Analg. 2020 Dec;131(6):1708-1720. doi: 10.1213/ANE.0000000000005023. Anesth Analg. 2020. PMID: 33186159 Review.
-
The endothelial glycocalyx: Barrier functions versus red cell hemodynamics: A model of steady state ultrafiltration through a bi-layer formed by a porous outer layer and more selective membrane-associated inner layer.Biorheology. 2019;56(2-3):113-130. doi: 10.3233/BIR-180198. Biorheology. 2019. PMID: 30664499
-
The glycocalyx: a novel diagnostic and therapeutic target in sepsis.Crit Care. 2019 Jan 17;23(1):16. doi: 10.1186/s13054-018-2292-6. Crit Care. 2019. PMID: 30654825 Free PMC article. Review.
Cited by
-
PIGO-CDG: A case study with a new genotype, expansion of the phenotype, literature review, and nosological considerations.JIMD Rep. 2023 Sep 20;64(6):424-433. doi: 10.1002/jmd2.12396. eCollection 2023 Nov. JIMD Rep. 2023. PMID: 37927489 Free PMC article.
-
An oligogenic case of severe neonatal thrombocytopenia and a purportedly benign variant in GFI1B requiring reinterpretation.Platelets. 2023 Dec;34(1):2237592. doi: 10.1080/09537104.2023.2237592. Platelets. 2023. PMID: 37577973
-
Nutrition interventions in congenital disorders of glycosylation.Trends Mol Med. 2022 Jun;28(6):463-481. doi: 10.1016/j.molmed.2022.04.003. Epub 2022 May 10. Trends Mol Med. 2022. PMID: 35562242 Free PMC article. Review.
-
The development of end stage renal disease in two patients with PMM2-CDG.JIMD Rep. 2022 Jan 10;63(2):131-136. doi: 10.1002/jmd2.12269. eCollection 2022 Mar. JIMD Rep. 2022. PMID: 35281664 Free PMC article.
-
Treatment Options in Congenital Disorders of Glycosylation.Front Genet. 2021 Sep 10;12:735348. doi: 10.3389/fgene.2021.735348. eCollection 2021. Front Genet. 2021. PMID: 34567084 Free PMC article. Review.
References
REFERENCES
-
- Ng BG, Freeze HH. Perspectives on glycosylation and its congenital disorders. Trends Genet. 2018;34(6):466-476.
-
- Al Teneiji A, Bruun TU, Sidky S, et al. Phenotypic and genotypic spectrum of congenital disorders of glycosylation type I and type II. Mol Genet Metab. 2017;120(3):235-242.
-
- Jaeken J. Congenital disorders of glycosylation. Ann N Y Acad Sci. 2010;1214:190-198.
-
- Verheijen J, Tahata S, Kozicz T, et al. Therapeutic approaches in congenital disorders of glycosylation (CDG) involving N-linked glycosylation: an update. Genet Med. 2020; 22(2):268-279.
-
- Truin G, Guillard M, Lefeber DJ, et al. Pericardial and abdominal fluid accumulation in congenital disorder of glycosylation type Ia. Mol Genet Metab. 2008;94(4):481-484.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
